Francis McCafferty, MD
Allergy & Immunology · Stockbridge, GANPI 1417997339
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,984 of the $18,115 with a category attached, or 71.7%. 41 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 34.2% of the total.
Across 560 payments — averaging $32.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$6K
- Sanofi$2K
- GSK$2K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- CSL Behring$978
- plus $5K from 35 others
Across 43 payments — averaging $2756.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$77K
- Novartis$31K
- Genentech, Inc.$7K
- Alk-abello, Inc$4K
What the payments were for
- Consulting fees$530%
- Speaking & faculty fees$4,45025%
- Travel & lodging$5243%
- Food & beverage$12,98472%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,115 in reported general payments places this provider in the 80th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 16 | $587,695 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 43 | $243,548 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $180,286 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 178 | $135,700 |
| XolairOmalizumab | 26 | $86,854 |
| Dupixent SyringeDupilumab | 21 | $75,408 |
| TezspireTezepelumab-Ekko | 12 | $50,756 |
| Dupixent PenDupilumab | 13 | $48,453 |
| NucalaMepolizumab | 12 | $40,636 |
| Epinephrine | 152 | $31,396 |
| Spiriva RespimatTiotropium Bromide | 36 | $28,558 |
| Advair HfaFluticasone Propion/Salmeterol | 58 | $24,781 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $23,094 |
| SymbicortBudesonide/Formoterol Fumarate | 73 | $22,850 |
| Ipratropium Bromide | 446 | $15,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda | $978 | $587,69516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Hyqvia | $1,095 | $423,83356 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $1,550 | $208,356253 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $1,491 | $83,00797 claims |
| Hikma Pharmaceuticals USAEpinephrine | $26 | $31,396152 claims |
| Boehringer IngelheimSpiriva Respimat | $141 | $28,55836 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $63 | $9,37418 claims |
| Covis Pharma GmbHAlvesco | $356 | $1,62619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Stockbridge
- Nathan SegallStockbridge$4K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Belinda GrahamSmyrna$94K
- Lily HwangRoswell$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.